Asia Pacific Molecular Diagnostics Market Size, Growth, Share & Trends Analysis
Asia Pacific Molecular Diagnostics Market by Product & Service (Kits, Instruments), Test Type (Lab, PoC), Sample (Blood, Urine), Technology (PCR, NGS, ISH), Application [Infectious (Hepatitis, HIV, HAI, Flu), Cancer (Breast, Lung)] - Forecast to 2031
OVERVIEW
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The Asia Pacific molecular diagnostics market, valued at US$3.85 billion in 2025, stood at US$4.22 billion in 2026 and is projected to advance at a resilient CAGR of 12.4% from 2026 to 2031, culminating in a forecasted valuation of US$7.58 billion by the end of the period. The large population in this region, along with a significant burden of infectious diseases in various countries, primarily explains this trend. Additionally, the growing availability of diagnostic services, particularly in underdeveloped healthcare settings, has significantly contributed to the increased use of this technology. Furthermore, rising healthcare spending, the expansion of capacity, and a greater understanding of the importance of early disease diagnosis have all played important roles in this upward trend.
KEY TAKEAWAYS
-
By CountryBy country, China held the largest share of the market in 2025.
-
By Product & ServiceBy product & service, the reagents & kits segment is expected to register the highest CAGR of 13.4% during the forecast period.
-
By Test TypeBy test type, the lab tests segment accounted for the largest market share of 81.8% in 2025.
-
By Sample TypeBy sample type, the blood, serum, and plasma segment accounted for the largest market share of 69.6% in 2025.
-
By TechnologyBy technology, the PCR segment accounted for the largest share of the market in 2025.
-
By ApplicationBy application, the infectious disease diagnostics segment is expected to dominate the market.
-
By TechniqueBy technique, multiplex testing accounted for the largest market share in 2025.
-
Clinical ApplicationBy clinical application, the diagnostics segment is expected to dominate the market.
-
By End UserBy end user, the diagnostic labs segment is expected to register the highest CAGR.
-
Competitive LandscapeDanaher (US), Roche (Switzerland), Illumina (US), bioMérieux (France), and Thermo Fisher Scientific (US) were identified as the star players in the market, which is supported by their strong market presence and extensive product portfolios.
-
Competitive LandscapeVela Diagnostics (Singapore), Savyon Diagnostics (Israel), and Uniogen OY (Finland) have distinguished themselves among startups and SMEs by securing strong footholds in specialized niche areas.
The Asia Pacific molecular diagnostics market is experiencing significant growth as healthcare systems across the region are increasingly focusing on enhancing the accuracy of diagnosis and increasing access to diagnostic testing. The recent rise in the need for the early diagnosis of infectious diseases, the increasing application of molecular diagnostic technologies in cancer and genetic analyses, and the enhancement of access to modern diagnostic technologies are some of the key factors that are driving the growth of this market.
TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS
The Asia Pacific molecular diagnostics market is undergoing a significant change as healthcare systems adapt to the rising testing demand. The growing adoption of decentralized and near-patient molecular testing is enhancing access to healthcare in remote and underserved areas. Additionally, the increased use of high-throughput PCR systems, multiplex assays, and next-generation sequencing is broadening testing capabilities. The rapid adoption of new technologies in emerging economies is transforming traditional testing models. Furthermore, the rising use of digital tools for test management is changing molecular diagnostic workflows across the region.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
MARKET DYNAMICS
Level
-
Increasing prevalence of infectious diseases and cancer
-
Rising use of point-of-care diagnostic tests
Level
-
High cost of molecular diagnostic instruments
-
Limited reimbursement coverage
Level
-
Increasing importance of companion diagnostics
-
Rising growth opportunities across developing markets
Level
-
Operational barriers and labor shortage
-
Changing regulatory landscape
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Driver: Increasing prevalence of infectious diseases and cancer
The region continues to experience a high burden of infectious diseases, along with a rising incidence of cancer, which is driving the demand for accurate and timely diagnostic solutions. Molecular diagnostics is increasingly being used to support early detection, disease monitoring, and treatment decisions, particularly in densely populated countries where testing volumes remain high. This sustained disease burden is a key factor supporting the growing adoption of molecular diagnostic technologies across the region.
Restraint: High cost of molecular diagnostic instruments
The high upfront cost of molecular diagnostic instruments remains a challenge in the Asia Pacific market, particularly in price-sensitive healthcare systems and developing countries. In addition to capital investment, ongoing expenses related to maintenance, reagents, and skilled personnel can limit adoption. These cost-related barriers may slow the pace of implementation of advanced molecular platforms in certain parts of the region.
Opportunity: Rising growth opportunities across developing markets
The emerging markets across the Asia Pacific present huge opportunities for the growth of the molecular diagnostics market, especially with the expansion of access to healthcare services in the region. Higher government initiatives towards improving the availability of diagnostic services, combined with the growing importance of early disease detection, as well as the increased adoption of newer diagnostic technologies, have fueled the demand for molecular diagnostics.
Challenge: Operational barriers and labor shortage
Limited availability of skilled personnel & operational constraints continue to restrict the effective use of molecular diagnostics (MDx) in several countries. Advanced testing requires trained professionals and well-established laboratory workflows, which are not yet consistently available. Strengthening technical training & improving operational capacity will be important to ensure the reliable and efficient use of molecular diagnostic technologies.
APAC MOLECULAR DIAGNOSTICS MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
 |
Application of rapid PCR-based molecular platforms for high-throughput infectious disease testing & decentralized diagnostic workflows. | Supports faster test turnaround, improves scalability, and enables efficient deployment across diverse testing environments. |
 |
Integrated molecular diagnostic systems for infectious disease testing, cancer diagnostics, and companion diagnostics in centralized labs. | Delivers high test accuracy, standardized results, and seamless integration across laboratory workflows. |
 |
Use of next-generation sequencing technologies for oncology profiling, genetic analysis, and large-scale genomic testing programs. | Delivers deep genomic insights, supports precision medicine strategies, and enables scalable high-throughput analysis. |
 |
MDx solutions for rapid identification of pathogens & monitoring of healthcare-associated infections (HAIs). | Enables timely detection, supports infection control strategies, and improves disease management outcomes. |
 |
Application of comprehensive molecular diagnostic instruments and assays for infectious disease testing, genetic analysis, and oncology diagnostics. | Supports high test accuracy, scalable testing workflows, and reliable performance across a wide range of applications. |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET ECOSYSTEM
The Asia Pacific molecular diagnostics ecosystem consists of key stakeholders and components across the entire value chain, including products & services, test types, sample types, technologies, applications, techniques, clinical applications, and end users. The stakeholders include manufacturers engaged in developing and introducing products, distributors who sell via third parties or e-commerce platforms, and R&D partners offering outsourced development and manufacturing support. End users include hospitals & clinics, diagnostic laboratories, and other end users that apply MDx solutions in carrying out diagnostics. These constitute the key stakeholders in the Asia Pacific molecular diagnostics supply chain.
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET SEGMENTS
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Asia Pacific Molecular Diagnostics Market, By Product & Service
By product & service, the market is segmented into reagents & kits, instruments, and services & software. In 2025, the reagents & kits segment accounted for the largest share, supported by their frequent use across molecular testing workflows. High testing volumes for infectious diseases, along with expanding assay availability, have resulted in steady and recurring demand for reagents and kits across the region.
Asia Pacific Molecular Diagnostics Market, By Test Type
By test type, the market is categorized into laboratory tests and PoC tests. In 2025, the laboratory tests segment held the largest share of the market, driven by their use in complex & high-throughput molecular testing. Centralized testing facilities continue to play a key role in handling large sample volumes and supporting standardized molecular diagnostic practices.
Asia Pacific Molecular Diagnostics Market, By Sample Type
Based on sample type, the market includes blood, serum, and plasma; urine; and other sample types. The blood, serum, and plasma segment accounted for the largest share due to their routine use & suitability for a wide range of molecular assays. These sample types support the reliable detection of pathogens and biomarkers, contributing to consistent testing demand.
Asia Pacific Molecular Diagnostics Market, By Technology
By technology, the market is segmented into polymerase chain reaction, isothermal nucleic acid amplification technology, DNA sequencing & next-generation sequencing, in situ hybridization, DNA microarrays, and other technologies. PCR dominated the market owing to its established use, cost-effectiveness, and suitability for large-scale infectious disease testing across many Asia Pacific countries.
Asia Pacific Molecular Diagnostics Market, By Application
By application, the market is divided into infectious disease diagnostics, oncology testing, genetic testing, and other applications. The infectious disease diagnostics segment accounted for the largest share, supported by the high burden of communicable diseases and ongoing demand for accurate and timely diagnosis across densely populated countries.
Asia Pacific Molecular Diagnostics Market, By Technique
By technique, the market includes multiplex testing and singleplex testing. The multiplex testing segment held the larger share in 2025, as it enables the simultaneous detection of multiple targets from a single sample, thereby improving efficiency and reducing the overall testing time in high-volume diagnostic settings.
Asia Pacific Molecular Diagnostics Market, By Clinical Application
Based on clinical application, the market is segmented into diagnostics and screening. The diagnostics segment accounted for the largest share in 2025, driven by the widespread use of molecular tests for disease confirmation, treatment guidance, and monitoring across various clinical conditions.
Asia Pacific Molecular Diagnostics Market, By End User
By end user, the market is categorized into hospitals & clinics, diagnostic laboratories, and other end users. Diagnostic laboratories represented the largest share of the market in 2025, reflecting their role in managing high test volumes and performing specialized molecular diagnostic procedures.
REGION
India to register highest CAGR in Asia Pacific molecular diagnostics market
India is expected to register the highest CAGR in the Asia Pacific molecular diagnostics market due to the rapid expansion of healthcare infrastructure and increasing access to diagnostic services. A high burden of infectious diseases, the rising incidence of cancer, and a large patient population are driving the sustained demand for molecular testing.
APAC MOLECULAR DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX
Danaher (Star) is a leading player in the Asia Pacific molecular diagnostics (MDx) market due to its strong portfolio of well-established molecular testing platforms, supported by continuous innovation & automation. The company benefits from broad assay menus and scalable systems, which drive recurring demand for consumables. Additionally, Danaher’s focus on workflow efficiency and test reliability has enabled it to maintain a strong competitive position across key molecular diagnostics applications.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
KEY MARKET PLAYERS
MARKET SCOPE
| REPORT METRIC | DETAILS |
|---|---|
| Market Size in 2025 (Value) | USD 3.85 Billion |
| Market Forecast in 2031 (Value) | USD 7.58 Billion |
| Growth Rate | CAGR of 12.4% from 2026–2031 |
| Years Considered | 2024–2031 |
| Base Year | 2024 |
| Forecast Period | 2026–2031 |
| Units Considered | Value (USD Million/Billion) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments Covered |
|
| Countries Covered | China, Japan, India, Australia, South Korea, Rest of Asia Pacific |
WHAT IS IN IT FOR YOU: APAC MOLECULAR DIAGNOSTICS MARKET REPORT CONTENT GUIDE
DELIVERED CUSTOMIZATIONS
We have successfully delivered the following deep-dive customizations:
| CLIENT REQUEST | CUSTOMIZATION DELIVERED | VALUE ADDS |
|---|---|---|
| Product Analysis | Product matrix, which provides a detailed comparison of the product portfolio of each company in the Asia Pacific molecular diagnostics market | Enables the easy comparison of competitors’ offerings, helping identify gaps, overlaps, and differentiation opportunities |
| Company Information | Additional five company profiles of players operating in the Asia Pacific molecular diagnostics market | Provides insights into competitors’ strategies, innovation focus, and partnerships, supporting strategic planning |
RECENT DEVELOPMENTS
- October 2025 : F. Hoffmann-La Roche Ltd. (Switzerland) announced a strategic collaboration with the Office for Attracting Strategic Enterprises (Hong Kong) to accelerate healthcare innovation. As part of the initiative, Roche plans to expand its presence in Hong Kong over the next five years through a joint effort between its Pharmaceutical and Diagnostics divisions.
- June 2025 : QIAGEN N.V. (Netherlands) partnered with GENCURIX (South Korea) to co-develop oncology assays for the QIAcuityDx platform, a high-performance digital PCR system designed for clinical diagnostics. The partnership marked an important step in expanding the range of in vitro diagnostic (IVD) assays available on the QIAcuityDx Four platform, improving access to digital PCR-based diagnostic solutions.
- February 2024 : Myriad Genetics, Inc. (US) collaborated with the National Cancer Center Hospital East (Japan) to evaluate the prognostic & predictive potential of molecular residual disease (MRD) testing. As part of the SCRUM-MONSTAR-SCREEN-3 study, Myriad’s ultra-sensitive Precise MRD test is being used to monitor circulating tumor DNA (ctDNA) over time in patients with various solid and hematological cancers.
- August 2023 : lllumina, Inc. (US) expanded its commercial operations in India by opening a new office and Solutions Center in Bengaluru.
Table of Contents
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
Methodology
The study involved major activities in estimating the current market size for the Asia Pacific Molecular Diagnostics Market. Exhaustive secondary research was done to collect information on the Asia Pacific Molecular Diagnostics Market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the Asia Pacific Molecular Diagnostics Market.
Secondary Research
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to, to identify and collect information for this study.
Primary Research
In the primary research process, various sources from the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources mainly include industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess prospects.
Market Size Estimation
The top-down and bottom-up approaches were used to estimate and validate the Asia Pacific Molecular Diagnostics Market’s total size. These methods were also used extensively to estimate the size of various subsegments in the market.
- The key players in the industry have been identified through extensive secondary research.
- Primary and secondary research have determined the revenues generated by leading players operating in the Asia Pacific Molecular Diagnostics Market.
- All percentage share, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
Data Triangulation
After arriving at the overall market size by applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
Molecular diagnostics is a technique used to identify and analyze nucleic acids or proteins at a molecular level. This technique assesses an individual’s genetic makeup to identify a predisposition to any particular disease or condition and diagnose it.
Stakeholders
- Senior Management
- End Users
- Finance/Procurement Department
- R&D Department
Report Objectives
- To define, describe, segment, and forecast the Asia Pacific Molecular Diagnostics Market by product & service, test type, sample type, technology, application, technique, clinical application, end user, and region
- To provide detailed information regarding the major factors (such as drivers, restraints, opportunities, and challenges) influencing market growth
- To analyze the micromarkets1 concerning individual growth trends, prospects, and contributions to the overall Asia Pacific Molecular Diagnostics Market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies2
- To track and analyze company developments, such as product launches & approvals, partnerships, acquisitions, agreements, and other developments
- To benchmark players within the Asia Pacific Molecular Diagnostics Market using the Company Evaluation Matrix framework, which analyzes market players on various parameters within the broad categories of business strategy, market share, and product offerings
- To study the impact of AI/Gen AI on the Asia Pacific Molecular Diagnostics Market, along with the macroeconomic outlook for each region
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This ReportPersonalize This Research
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
Let Us Help You
- What are the Known and Unknown Adjacencies Impacting the Asia Pacific Molecular Diagnostics Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Custom Market Research Services
We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements
Get 10% Free Customisation
Growth opportunities and latent adjacency in Asia Pacific Molecular Diagnostics Market